Development
Alto Neuroscience, Inc.
ANRO
$2.57
$0.197.98%
NYSE
| 12/31/2022 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 1.74M | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 8.06M | ||||
| Operating Income | -8.06M | ||||
| Income Before Tax | -7.65M | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -7.65M | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -7.65M | ||||
| EBIT | -8.06M | ||||
| EBITDA | -7.96M | ||||
| EPS Basic | -0.94 | ||||
| Normalized Basic EPS | -0.59 | ||||
| EPS Diluted | -0.94 | ||||
| Normalized Diluted EPS | -0.59 | ||||
| Average Basic Shares Outstanding | 8.16M | ||||
| Average Diluted Shares Outstanding | 8.16M | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||